Federal prosecutor reviews possible use of RICO law for Altoona-Johnstown

By Peter Smith / Pittsburgh Post-Gazette

U.S. Attorney David Hickton said his office is looking into whether a federal civil law on organized crime can be applied to the Roman Catholic Diocese of Altoona-Johnstown in the wake of a state grand jury report that said it had a history of clergy sexual abuse and coverup.

The report found that much of the abuse by diocesan priests dated back several decades, and neither the abuse nor any alleged coverup could be prosecuted under the statute of limitations.

But federal laws allow U.S. prosecutors to bring a civil case against an organization and seek an injunction or a consent decree to shape its future behavior, and such cases do not have a statute of limitations, he said.

Mr. Hickton said his office is looking into the case because it prosecuted one Altoona-Johnstown priest, Joseph Maurizio, who last month was sentenced to 17 years in federal prison for sexually abusing boys at a Honduras orphanage between 2004 and 2009.

U.S. Attorney David Hickton said his office is looking into whether a federal civil law on organized crime can be applied to the Roman Catholic Diocese of Altoona-Johnstown in the wake of a state grand jury report that said it had a history of clergy sexual abuse and coverup.

The report found that much of the abuse by diocesan priests dated back several decades, and neither the abuse nor any alleged coverup could be prosecuted under the statute of limitations.

But federal laws allow U.S. prosecutors to bring a civil case against an organization and seek an injunction or a consent decree to shape its future behavior, and such cases do not have a statute of limitations, he said.

Mr. Hickton said his office is looking into the case because it prosecuted one Altoona-Johnstown priest, Joseph Maurizio, who last month was sentenced to 17 years in federal prison for sexually abusing boys at a Honduras orphanage between 2004 and 2009.

Sourced From – http://www.post-gazette.com/news/state/2016/04/02/Federal-prosecutor-reviews-possible-use-of-RICO-law-for-Altoona-Johnstown/stories/201604020025

Anti-mafia campaigner in Sicily arrested on mafia-charges

An anti-mafia campaigner once hailed as a hero for blowing the whistle on organised crime has been arrested in Sicily on mafia-related charges.

Cement supplier Vincenzo Artale, 64, had publicly denounced efforts by local mobsters to extract protection money and had even helped founded an anti-mafia association a decade ago in Alcamo, the town between Palermo and Trapani where he had a small business.

But in the decade that followed, prosecutors allege Artale began using his anti-mafia façade as a cover for keeping shady local deals quiet, while doing business with some of Sicily’s biggest mafia bosses on the side.

“Yet again wiretappings have revealed that pretending to be anti-mafia is the perfect shield to mask businesses operating in the shadow of the mafia,” Teresa Principato, one of the prosecutors working on the case, told La Repubblica.

In 2006, Artale was lauded for his courage after he reported local Mafiosi who he said had tried to extort protection money from him. He was compensated  €250,000 from a state-run victim’s solidarity fund and founded a local anti-racket association.

But not long afterwards, prosecutors say Artale began working for a local mobster thought to be one of the key associates of the fugitive Cosa Nostra leader who is Italy’s most wanted man: Mattia Messina Denaro.

According to Italian reports, the gangsters struck a deal with Artale – he would shield them from exposure and in return they would force local construction companies to buy his cement.

His cement business boomed.  But Artale’s sudden wealth triggered suspicion among the townsfolk and soon his anti-mafia double agent game was up. Local builders joined forces to denounce that they were being intimidated to buy his cement, triggering the two-year-long investigation that led to his arrest Wednesday.

He is the latest of several high-profile Sicilian businessmen caught privately working with the mafia while publicly decrying organised crime.

Last year, the head of the Palermo chamber of commerce Roberto Helg, who had publicly denounced the mafia’s extortion practices, was secretly filmed taking a €100,000 bribe in exchange for a pastry shop’s retail space in the airport.

Sourced From  – http://www.telegraph.co.uk/news/2016/03/31/anti-mafia-campaigner-in-sicily-arrested-on-mafia-charges/

Deadmau5 Sues Vape Company for Trademark Infringement

MARCH 31, 2016 6:56pm PT by Ashley Cullins

The deadmodz vape brand is confusing deadmau5 fans who think the electronic music star is behind the electronic cigarette line, according to the lawsuit.

Electronic dance music master Joel Zimmerman says West Coast Vape Supply is intentionally infringing on his deadmau5 trademark, according to a federal lawsuit filed on Thursday in California.The deadmodz electronic cigarette line is trying to capitalize on Zimmerman’s fame, and according to the lawsuit the products “overlap with, are closely related to deadmau5’s goods and services and/or represent a natural zone of expansion for deadmau5, and such goods are or would be marketed and sold to the same types of consumers through the same channels of trade.”

Zimmerman is suing for trademark infringement and false association, and is seeking statutory and punitive damages and a permanent injunction to ban West Coast Vape from using deadmodz.

His attorney Irene Lee sent a statement to The Hollywood Reporter saying they’re suing to protect the artist’s trademark and his fans.

“Our client faces unscrupulous people trying to take advantage goodwill associated with his intellectual property and his fame,” Lee writes. “We are grateful for our fans and believe it’s our obligation to make sure our fans are not duped into buying things that deadmau5 did not authorize.”

The lawsuit claims deadmau5 is not only a trademark, but a brand Zimmerman has been building for more than a decade. It also explains the origins of his onstage persona.

In 2002 Zimmerman took his computer apart and found a dead mouse inside. When he posted the story online, people started referring to him as “dead mouse guy.” He embraced the new nickname and tried to change is screen name to “deadmouse” but found the Internet Relay Chat channel he was using limited usernames to eight characters. Using leet spelling, he became deadmau5.

Not only is the name “deadmodz” similar to “deadmau5,” Lee argues, but also the vape company copied the bubble font Zimmerman uses in his logo.

Lee shared this photo, which is an exhibit to the suit:
Screen Shot 2016-04-02 at 2.06.57 AM

In an effort to avoid the litigation, Zimmerman’s transactional attorney Dina LaPolt sent several letters to Alham Benyameen, the principal of West Coast Vape.

After an initial cease and desist letter, sent on Feb. 5, Benyameen substantially changed his website and logo design.

In response LaPolt made it clear that wasn’t good enough and tried again to settle out of court in a Feb. 19 letter.

“Please understand that your attempted changes do not negate that fact that you have violated and continue to violate our client’s rights, and thus are liable for, among other things, trademark and copyright infringement and attendant damages,” LaPolt writes. “In fact, your changes only highlight your acknowledgement and concession of wrongdoing, which admittedly is willful, knowing and intentional.”

When they didn’t respond, Lee prepared the suit.

“Instead of conceding their wrongdoing and agreeing to comply with our requests, they refused to acknowledge deadmau5’s intellectual property rights and their wrongdoing, necessitating this legal action,” she writes in her statement to THR. “We intend to vigorously protect deadmau5’s rights.”

West Coast Vape did not immediately respond to a request for comment.

Sourced From – http://www.hollywoodreporter.com/thr-esq/deadmau5-sues-vape-company-trademark-879815

Zoloft (sertraline hydrochloride) Recall Info

drug-recalls

Sourced From Our Friends @ https://www.recallguide.org/drug/zoloft/

Zoloft® is an antidepressant medication classified as a selective serotonin reuptake inhibitor (SSRI), generally prescribed to adults to treat major depression and anxiety disorders and, less commonly, for vascular headaches and premature ejaculation. It is an oral medication originally brought to the market by American pharmaceutical manufacturer Pfizer and is available in 25mg, 50mg, and 100mg capsules.

Side Effects & Adverse Reactions

Common side effects include fatigue, insomnia, nausea, dry mouth, headache, diarrhea, dizziness, weight gain, and sexual dysfunction (difficulty achieving arousal, erection and/or orgasm).

As with all antidepressants, Zoloft carries the FDA’s black box warning due to an increased risk of suicidal thoughts/ideation and actions, especially in children and young adults. (fda.gov)

The use of Zoloft during the first trimester of pregnancy is associated with increased risks of the following birth defects: omphalocele (abdominal wall defects), anal atresia (malformation of the anus/rectum), limb reduction, and septal (heart) defects.(ncbi.nlm.nih.gov)

Like many other antidepressant medications, the discontinuation of regular use of Zoloft can cause numerous unpleasant withdrawal side effects, including flu-like symptoms (nausea, vomiting, sweating, headaches, diarrhea), sleep disturbances (insomnia, nightmares, fatigue), sensory/movement disturbances (vertigo, dizziness, “zap” like electrical sensations in the brain or nerve paths), and mood disturbances (anxiety, dysphoria, agitation). Most cases of these withdrawal symptoms are mild and resolve themselves after 1-4 weeks.

Possible Adverse Interactions

Zoloft should not be taken with, or immediately after stopping use of, monoamine oxidase inhibitors (MAOIs), another class of commonly used antidepressants, as this can cause serotonin syndrome or serotonin toxicity, a condition that can be fatal.

It is also contraindicated for use with the antipsychotic medication pimozide (Orap) due to the risk of serious heart problems. The concentrated form also contains an alcohol solution, so it is recommended not to take it with Antabuse, a medication used to treat alcoholism. Grapefruit and grapefruit juice should also be avoided, as it can increase the levels of Zoloft in the body.

Screen Shot 2016-04-01 at 3.36.13 PM

Legal Issues

Pfizer has over 1,000 lawsuits pending against them regarding the use of Zoloft causing birth defects in pregnancy. In June 2015, a jury in Philadelphia, PA sided with the defendant (Pfizer) in a case wherein the plaintiffs alleged that Pfizer did not sufficiently warn patients of the potential for birth defects, finding that the drug’s label adequately warned physicians to weigh and discuss the benefits and risks of use before prescribing it (Robinson v. Wolters Kluwer Health Inc. and Pfizer, Inc.). This is the second such judgment in favor of Pfizer regarding birth defects and use of Zoloft in as many trials. (bloomberg.com)

Zoloft was also the subject of a consumer fraud class action lawsuit that was filed in 2013 in California. The case, Plumlee vs. Pfizer Inc., centered on claims by plaintiff Laura Plumlee that she had taken the drug as prescribed for 3 years with absolutely no effect. The suit alleged that Pfizer deliberately omitted from labeling that there had been studies conducted that found Zoloft to be no more effective than a placebo, and that their marketing and advertising regarding its effectiveness was misleading. The plaintiff’s first claim was dismissed in March 2014, not due to the argument of effectiveness or lack thereof, but due to time-barring. Plumlee had last used Zoloft in 2008, but did not file the lawsuit until 2013. She was given the opportunity to amend her claim and re-file, but the suit was ultimately dismissed with prejudice in September 2014.

FDA Safety Alerts

July, 2006

Food and Drug Administration Labeling Changes indicate several changes but this specific Alert was issued warning of increased risk of Neonatal Persistent Pulmonary Hypertension in mothers taking the drug (fda.gov).

December 14, 2011

The FDA warns of pregnancy risks in SSRI’s in general, including Zoloft. (fda.gov).

July 26, 2011

FDA warns of serious CNS reactions in patients taking the antibiotic linezolid (Zyvox) and certain psychiatric serotonin drugs, including Zoloft. (fda.gov)

Manufacturer Warnings

An undated warning letter from Pfizer alerts healthcare providers to the warnings and label changes regarding detrimental interactions of Zoloft with pimozide (Orap) and MAOIs (fda.gov).

FDA Labeling Changes

September 2014

A labeling adjustment was made to the drug interactions to remove previous additions of QT prolongation, Torsades de Pointes, and ventricular tachycardia – all types of cardiac arrhythmia (irregular heart rhythm) (fda.gov).

February 2013

Diabetes mellitus (scientific name for both Type 1 and Type 2 diabetes) was added to the list of events observed during the post-marketing evaluation of Zoloft. (fda.gov)

December 2012

Contraindications and warnings were added regarding the types of drugs or substances that will interact with use of Zoloft and possibly cause serotonin syndrome, expanding upon the warnings issued in January 2009 (fda.gov).

August 2011

Information was added to the packaging label to advise caution when co-administering Zoloft with drugs that may enhance serotonergic neurotransmission (transmission/absorption of serotonin) due to possibility for interaction. In addition, a precaution was added regarding laboratory testing: patients using Zoloft were reported to have received false positives on urine immunoassay screening tests for benzodiazepines(a class of frequently abused anti-anxiety medications) such as clonazepam (fda.gov).

January 2009

A warning was issued regarding the potential for the potentially fatal complication serotonin syndrome, also known as serotonin storm or serotonin toxicity, or a similar condition called neuroleptic malignant syndrome. Both of these conditions can occur when Zoloft is taken in combination with MAOIs (such as selegiline or phenelzine), or other drugs that alter the neurotransmission of serotonin (fda.gov).

March 2008

Precautions were added to the label making changes to the following subjects: abnormal bleeding as a potential side effect, and interactions with drugs that interfere with the clotting and flow of blood (Non-selective NSAIDs, aspirin, warfarin, etc.) (fda.gov).

Uses

Zoloft® is an antidepressant medication classified as a selective serotonin reuptake inhibitor (SSRI), generally prescribed to adults to treat major depression and anxiety disorders and, less commonly, for vascular headaches and premature ejaculation. It is an oral medication originally brought to the market by American pharmaceutical manufacturer Pfizer and is available in 25mg, 50mg, and 100mg capsules.

Screen Shot 2016-04-01 at 3.39.41 PM

History

Sertraline was the result of many levels of experimentation by Pfizer chemists, beginning in the early 1970’s with the invention of multiple psychoactive compounds that were based on the structures of some of the earliest available antipsychotic medications. These experiments would eventually result in the development of many neurotransmitter reuptake inhibitors, the most potent and selective of which would go on to be tested in vivo (on living organisms, including human trials) and dubbed sertraline. None of the scientists responsible for its creation were anticipating the production of an SSRI type of antidepressant, so the discovery is considered a happy accident.

Zoloft was approved by the FDA on the recommendation of the Psychopharmacological Drugs Advisory Committee in 1991. It was also made available in the United Kingdom the previous year, and in Australia in 1994. It was only approved for prescription to adults over the age of 18 until 2002, when the FDA approved its use in children over age 6 to treat severe cases of obsessive-compulsive disorder. In 2005, the FDA issued a black box warning for all antidepressants, including sertraline, concerning suicidal thoughts and behaviors in children; this warning was amended in 2007 to include the possibility of suicidal tendencies in young adults aged 18 to 24.

The patent for Zoloft expired in the US in 2006, allowing for the availability of sertraline in its generic form. Other brand names for sertraline include Lustral and Asentra. In 2013, it was the most prescribed antidepressant and second-most prescribed psychiatric medication in the United States. (psychentral.com)

For Full Article – https://www.recallguide.org/drug/zoloft/